Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma

[1]  R. Vollmer,et al.  Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma. , 2001, American journal of clinical pathology.

[2]  A. Bateman,et al.  IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma , 2001, Genes and Immunity.

[3]  W. Renner,et al.  A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels , 2000, Journal of Vascular Research.

[4]  M. Bottomley,et al.  Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.

[5]  T. Danielsen,et al.  The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts , 2000, British Journal of Cancer.

[6]  V. Pravica,et al.  Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. , 1999, Human immunology.

[7]  B. Smoller,et al.  Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[8]  K. Alitalo,et al.  Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. , 1999, Melanoma research.

[9]  A Collins,et al.  Mapping a disease locus by allelic association. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Dummer,et al.  Interleukin‐10 is a growth factor for human melanoma cells and down‐regulates HLA class‐I, HLA class‐II and ICAM‐1 molecules , 1997, International journal of cancer.

[11]  E. Maxwell,et al.  Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism , 1996, The Journal of experimental medicine.

[12]  K. Claffey,et al.  Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis , 1996, Cancer and Metastasis Reviews.

[13]  S. Soker,et al.  Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. , 1995, Cancer research.

[14]  Jurg Ott,et al.  Handbook of Human Genetic Linkage , 1994 .

[15]  O. Olerup,et al.  HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. , 1992, Tissue antigens.

[16]  R. MacKie,et al.  Cutaneous malignant melanoma, Scotland, 1979-89 , 1992, The Lancet.

[17]  B. Berse,et al.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. , 1992, Molecular biology of the cell.

[18]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[19]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[20]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[21]  K. Calman,et al.  MALIGNANT MELANOMA IN SCOTLAND 1979-1983 , 1985, The Lancet.

[22]  Langeveld Mj.  Letter: Fenestrated tracheostomy tubes. , 1973 .

[23]  P. Harden,et al.  Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. , 2002, Journal of the American Society of Nephrology : JASN.